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Abstract
Background: Marrow stromal cells (MSC), the non-hematopoietic precursor cells in bone marrow, are
being investigated for therapeutic potential in CNS disorders. Although in vitro studies have suggested that
MSC may be immunologically inert, their immunogenicity following transplantation into allogeneic
recipients is unclear. The primary objective of this study was to investigate the cellular immune response
to MSC injected into the striatum of allogeneic recipients (6-hydroxydopamine [6-OHDA]-hemilesioned
rats, an animal model of Parkinson's disease [PD]), and the secondary objective was to determine the
ability of these cells to prevent nigrostriatal dopamine depletion and associated motor deficits in these
animals.
Methods: 5-Bromo-2-deoxyuridine (BrdU) – labeled MSC from two allogeneic sources (Wistar and ACI
rats) were implanted into the striatum of adult Wistar rats at the same time as 6-OHDA was administered
into the substantia nigra. Behavioral tests were administered one to two weeks before and 16–20 days
after 6-OHDA lesioning and MSC transplantation. Immunocytochemical staining for T helper and T
cytotoxic lymphocytes, microglia/macrophages, and major histocompatibility class I and II antigens was
performed on post-transplantation days 22–24. MSC were detected with an anti-BrdU antibody.
Results:  Tissue injury due to the transplantation procedure produced a localized cellular immune
response. Unexpectedly, both sources of allogeneic MSC generated robust cellular immune responses in
the host striatum; the extent of this response was similar in the two allograft systems. Despite these
immune responses, BrdU+ cells (presumptive MSC) remained in the striatum of all animals that received
MSC. The numbers of remaining MSC tended to be increased (p = 0.055) in rats receiving Wistar MSC
versus those receiving ACI MSC. MSC administration did not prevent behavioral deficits or dopamine
depletion in the 6-OHDA-lesioned animals.
Conclusion: MSC, when implanted into the striatum of allogeneic animals, provoke a marked immune
response which is not sufficient to clear these cells by 22–24 days post-transplantation. In the experimental
paradigm in this study, MSC did not prevent nigrostriatal dopamine depletion and its associated behavioral
deficits. Additional studies are indicated to clarify the effects of this immune response on MSC survival and
function before initiating trials with these cells in patients with PD or other neurodegenerative disorders.
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Background
The standard treatment for Parkinson's disease (PD) for
several decades has been the dopamine precursor levo-
dopa. However, long-term administration of levodopa
eventually results in decreased efficacy and the emergence
of side effects including dyskinesias and psychoses. Inter-
est has therefore grown in cellular restoration of striatal
dopaminergic innervation in PD patients. Intrastriatal
implantation of fetal mesencephalic tissue has resulted in
long-term reductions of motor deficits [1,2] and normali-
zation of striatal dopamine levels [3] in some patients, but
this approach is limited by ethical and practical concerns,
as well as the development of dyskinesias. In addition,
although the brain was traditionally regarded as "immu-
nologically privileged," long-term survival of fetal mesen-
cephalic grafts in the adult brain is poor due to immune
rejection and possibly other mechanisms [4]. More recent
studies have suggested that stem cells may be useful in
treating PD [5-7]. These cells offer significant advantages
over fetal tissue for treatment of PD, including their ability
to be expanded in culture and receive transfected genes
and their potential for migration and differentiation in
host tissue [8]. However, ethical and logistical issues sim-
ilar to those for fetal mesencephalon transplantation also
apply to human embryonic stem cell therapy.
Bone marrow stromal cells (MSC), the non-hematopoi-
etic precursor cells (i.e. mesenchymal stem and progenitor
cells) in bone marrow, offer an alternative source of cells
for treatment of neurodegenerative diseases and central
nervous system (CNS) injury. These cells normally differ-
entiate into bone, cartilage, and adipose tissue [9], but can
be experimentally induced to differentiate into cells with
surface markers characteristic of neurons [10,11]. When
injected into the brain or administered systemically, MSC
can migrate to sites of injury, proliferate, and engraft [12-
15]. These cells offer several advantages over other sources
of stem-like precursor cells as therapy for PD: they are eas-
ily harvested, isolated, and purified, can be produced in
large quantities, and their use does not pose ethical con-
cerns. Potential roles for MSC in treatment of PD include
their use as vectors for delivery of gene products to sites of
tissue injury [16-19], facilitation of recovery from neuro-
nal damage by replacing injured and/or lost cells [20-22],
and production of trophic factors promoting survival and
regeneration of host tissue [23-26]. In support of these
therapeutic concepts, modest improvements in neurolog-
ical function have been reported following MSC adminis-
tration in animal models of PD, stroke, and acute CNS
injury [26-29]. Although patients could be treated with
their own MSC (an autologous transplant) to avoid possi-
ble immune rejection of the administered cells, the use of
previously harvested and in vitro-expanded MSC from
other individuals (an allogeneic transplant) would avoid
the necessity for the patient to undergo bone marrow aspi-
ration, and would allow rapid administration of previ-
ously expanded (and, if warranted, genetically modified)
MSC.
Surprisingly little is known about the CNS immune
response to locally administered MSC. However, a large
number of in vitro studies have suggested that MSC pos-
sess immunosuppressive properties and, therefore, may
not induce an immune response (for review see [30]). For
example, MSC inhibit T cell proliferation induced by allo-
geneic lymphocytes or mitogens [31-33] and inhibit both
naïve and memory T cell activation [34]. These effects are
independent of major histocompatibility complex
(MHC) expression (MSC express MHC class I antigens
and low levels of MHC class II antigens and co-stimula-
tory molecules) [33], and have been attributed, in part, to
the secretion of soluble factors that inhibit production of
inflammatory cytokines and increase production of
immunosuppressive ones [32,35]. However, whether
MSC exert these immunosuppressive effects in vivo is
unclear. In support of this possibility, MSC transplanta-
tion prolongs survival of skin allografts in baboons [31],
allows growth of tumor cells otherwise rejected by immu-
nocompetent recipients [36], and attenuates acute graft-
versus-host disease after allogeneic bone marrow trans-
plantation [37,38]. Conversely, other studies have
reported that MSC do not prevent the graft-versus-host
response [39,40]. There also is no consensus as to whether
MSC are immunogenic in vivo. In some studies, transplan-
tation of allogeneic or xenogeneic MSC into immuno-
competent animals was not associated with a detectable
host immune response [12,15,25,41,42], whereas in oth-
ers, an immune response and/or rejection of MSC were
observed [39,43-47]. Survival of allogeneic MSC trans-
planted into the CNS is low [12,28,45], suggesting that
they may be targeted for removal by the host immune sys-
tem.
The objectives of the present study were to characterize the
local cellular immune response to allogeneic MSC after
transplantation into the striatum of unilaterally 6-hydrox-
ydopamine (6-OHDA) – lesioned rats, a well-character-
ized animal model of PD, as well as the ability of these
cells to improve motor function in this model. Two types
of allografts were employed: (1) MSC obtained from the
inbred ACI strain were implanted into Wistar rats, and (2)
Wistar MSC were implanted into Wistar rats from a differ-
ent breeding colony. Because Wistar is an outbred, ran-
dom-bred strain, tissues exchanged between Wistar rats
are allografts [48]. Rejection of fetal CNS grafts occurs
with both types of allografts, although it occurs more rap-
idly in grafts between unrelated inbred strains than in
grafts between rats of the same outbred strain (i.e. Wistar-
to-Wistar or Sprague-Dawley-to-Sprague-Dawley) [49].
We hypothesized that if a cellular immune responseJournal of Neuroinflammation 2009, 6:17 http://www.jneuroinflammation.com/content/6/1/17
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occurs in the brain following local administration of allo-
geneic MSC, then the extent of this response might differ
between these two allogeneic systems.
Methods
Animal welfare
The protocols used in this study were approved by the
Institutional Animal Care and Use Committee at William
Beaumont Hospital, Royal Oak, Michigan, USA
Animals and unilateral 6-OHDA lesioning
Adult female Wistar rats (Crl:WI, Charles River Laborato-
ries, Raleigh, North Carolina, USA), weighing 200–225 g
were housed in pairs with free access to food and water.
After completion of baseline behavioral testing (see
below), animals were anesthetized with sodium pento-
barbital (25–40 mg/kg, i.p.) and received a unilateral ster-
eotaxic injection of 6-OHDA hydrobromide (Sigma
Chemical Company, St. Louis, Missouri, USA) into the
substantia nigra. Briefly, 4 μg of 6-OHDA in 2 μl of saline-
0.1% ascorbate solution was infused over a 4 min period
via a 30 gauge cannula at the following coordinates [50]:
5.0 mm posterior to bregma, 2.0 mm lateral to the mid-
line, and 7.4 mm ventral from the skull surface. Our
intention was to generate partial, rather than complete,
lesions, similar to the extent of nigrostriatal dopamine
depletion in PD patients; our preliminary studies found
that this concentration of 6-OHDA produced a 70–95%
loss of striatal dopamine in most animals. The cannula
was left in place for 2 min following infusion to allow dif-
fusion of the solution. Desipramine (Sigma, 15 mg/kg,
i.p.) was administered 30 to 60 min before 6-OHDA to
protect noradrenergic terminals.
MSC preparation for transplantation
Male rat MSC from the outbred Wistar strain (Hsd:WI,
Harlan Sprague-Dawley, Inc.) and the inbred ACI strain
(ACI, Harlan Sprague-Dawley, Inc.) were provided by
Theradigm, Inc. (Baltimore, Maryland, USA) as frozen
vials of cells (passage #4). Flow cytometric data provided
by Theradigm, Inc. indicated that these MSC were positive
for CD44 (ACI MSC 87.3%, Wistar MSC 76.9%), CD73
(ACI MSC 53.2%, Wistar MSC 63.8%), CD90 (ACI MSC
98.1%, Wistar MSC 96.6%), and MHC class I antigens (no
data available for ACI MSC; Wistar MSC 79.5%), and neg-
ative for CD31, CD45, and MHC class II antigens. These
results are similar to those published previously for rat
and human MSC [51-53]. Cells were rapidly thawed, then
cultured in alpha minimal essential medium (MEM;
Gibco, Invitrogen Corporation, Carlsbad, California,
USA) containing L-glutamine, supplemented with 10%
fetal bovine serum (FBS, provided by Theradigm, Inc.)
and antibiotic-antimycotic (Penicillin, Streptomycin, and
Amphotericin B; Gibco). Cells were cultured at 37°C in
5% CO2 for 8–9 days, replacing the culture medium twice.
5-Bromo-2-deoxyuridine (BrdU; Calbiochem; 10 μM)
was added to the medium 72 hr before the cells were har-
vested. BrdU labeling efficiency exceeded 95% for both
strains of MSC (data not shown). For transplantation,
MSC were detached by brief incubation with 0.25%
trypsin, washed once with phosphate buffered saline
(PBS), then resuspended in PBS to 5 × 104 live cells/μl.
Cell viability, estimated by trypan blue dye exclusion,
ranged from 83–95%. Viability was similar for ACI- and
Wistar-derived MSC. Cells were kept on ice and used
within 1 hr.
Intrastriatal transplantation of MSC
Four striatal sites on the same side as the 6-OHDA lesion
were selected for MSC transplantation at the following
coordinates [50]: (1) 0.6 mm rostral to bregma, 2.5 mm
lateral to the midline, 4.5 mm and 6.0 mm ventral from
the skull surface; and (2) 0.5 mm rostral to bregma, 3.5
mm lateral to the midline, 4.5 and 6.0 mm ventral from
the skull surface. Immediately after 6-OHDA infusion,
animals (n = 6/group) received a 4 μl suspension of MSC
(~200,000 cells) into each of the sites using a 22 or 26
gauge Hamilton microsyringe attached to a microinjector
unit on the stereotaxic apparatus. Cells were injected at a
rate of 0.5 μl/min, and the needle was left in place for 2
min before slowly retracting it. Control animals (n = 6/
group) included similarly lesioned rats receiving infu-
sions of PBS rather than MSC, and non-lesioned, naïve
rats (for behavioral studies).
Behavioral procedures
Behavioral tests were administered one to two weeks prior
to the day on which the 6-OHDA lesioning and MSC
administration were performed, in order to establish a
baseline for normal performance, and were repeated at
16–20 days following the lesioning/transplantation pro-
cedure. The tests were drug-induced rotational behavior
[54], stepping test [55], limb use asymmetry test ("cylin-
der test," [56]), bilateral tactile stimulation test ("adhesive
removal test," [56]), and rotarod test [57].
Drug-induced rotational behavior
Animals were tested for both apomorphine- and amphet-
amine-induced rotational behavior. Challenges with apo-
morphine and amphetamine assess different areas in the
dopamine system: apomorphine stimulates dopaminer-
gic receptors whereas amphetamine stimulates the release
of dopamine [54]. Apomorphine-induced rotational
behavior was measured for 60 min following a subcutane-
ous injection of apomorphine (Sigma; 0.05 mg/kg, in
0.9% saline-0.1% ascorbate solution). Amphetamine-
induced rotational behavior was measured for 120 min
following intraperitoneal injection of d-amphetamine
sulfate (Sigma; 1.5 mg/kg, in 0.9% saline).Journal of Neuroinflammation 2009, 6:17 http://www.jneuroinflammation.com/content/6/1/17
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Forelimb stepping test
The animal was held by the experimenter so that one fore-
paw rested on a smooth table surface while the other
limbs were restrained. The number of adjusting steps was
counted while the animal was moved sideways along the
table surface (90 cm in 5 sec) in the forehand direction,
with both forelimbs. A reduced stepping rate with the con-
tralateral limb occurs with a 50–60% loss of dopaminer-
gic neurons in the substantia nigra, and the level of
performance gradually diminishes with larger lesions
[58].
Cylinder test
Animals were placed in a 25 cm diameter (46 cm high)
transparent cylinder and behavior was videotaped in the
dark for 5 min. Rearing behavior was analyzed, and the
number of contacts made by each forepaw with the cylin-
der wall was determined from the videotapes.
Bilateral tactile stimulation test
Animals were tested for unilateral sensorimotor impair-
ments before and after MSC implantation using the adhe-
sive-removal ("sticky label") sensorimotor test [56]. Two
small pieces of adhesive-backed paper (1.2 cm in diame-
ter) were used as tactile stimuli on the distal-radial region
of each forelimb, and the time required for the animal to
remove each stimulus from the forelimbs was recorded.
Rotarod test
The rotarod apparatus (Economex Accelerating Rota-Rod,
Columbus Instruments, Columbus, Ohio, USA) measures
the time that an animal is able to remain on a rod rotating
at different speeds. Motor deficits related to limb dexterity
and speed of movement lead to the animal falling off the
rotating cylinder; thus, this test is useful for evaluation of
motor impairments in animal models of Parkinsonism.
Animals were placed on the rod rotating at an accelerating
speed from 0 to 48 rpm in 480 sec. The time that the ani-
mal remained on the rod and the maximal speed reached
prior to falling were recorded.
Histology and immunohistochemistry
Animals were sacrificed 22 to 24 days after MSC trans-
plantation, following behavioral testing on post-trans-
plantation days 16–20. The gap of a few days between
behavioral testing and sacrifice was necessitated by the
staggering of the lesioning/transplantation procedures
over several days, with subsequent staggering of behavio-
ral testing to coincide with the surgery dates. Following
induction of deep anesthesia by pentobarbital (60–80
mg/kg, i.p.), animals were intracardially perfused with 0.1
M PBS, followed by 4% paraformaldehyde in PBS. Brains
were removed and post-fixed for 4 h in the same fixative,
then cryoprotected in 0.1 M PBS with 20% sucrose over-
night on ice. Each brain was cut into two coronal pieces,
with one piece including the striatum and the other piece
including the substantia nigra, then rapidly frozen on dry
ice and stored at -70°C. Striatal and substantia nigra sec-
tions were subsequently cut at 20 μm thickness on a cryo-
stat. Sections were collected, thaw-mounted on
microscope slides (Superfrost Plus, Cardinal Health,
McGaw Park, Illinois, USA) and stored at -20°C.
BrdU immunohistochemistry
Every ninth section throughout the striatum was stained
for BrdU. After three washes in 0.1 M Tris buffered saline
(TBS), pH 7.6, with 0.1% Triton X-100 (TBS-T), sections
were pre-treated for 30 min in boiling citrate buffer, pH
6.0 (Antigen Unmasking Solution, Vector Laboratories,
Burlingame, California, USA), then cooled for 20 min at
room temperature in the same solution. Sections were
washed in TBS-T, then treated with 3% hydrogen peroxide
and 10% methanol in TBS for 30 min to quench endog-
enous peroxidase activity. After three washes in TBS-T,
nonspecific binding of immunoglobulins was blocked by
1 hr incubation with 10% normal horse serum (NHS) in
TBS-T containing 2% bovine serum albumin (BSA). Mon-
oclonal anti-BrdU antibody (Calbiochem, San Diego, Cal-
ifornia, USA) was diluted 1:200 in TBS-T/1% NHS/2%
BSA, then applied to the sections and allowed to incubate
overnight at 4°C. Sections were then washed with TBS
and incubated with biotinylated, rat-preabsorbed, horse
anti-mouse IgG (Vector, 1:200) in TBS-T/1% NHS/2%
BSA for 1 hr. Following washes in TBS, sections were incu-
bated for 1 hr with avidin-biotin horseradish peroxidase
complex (Vectastain Elite ABC kit, Vector) diluted 1:100
in 0.1 M TBS. After additional washes in TBS, the sections
were developed using 3,3-diaminobenzidine with nickel
enhancement (DAB kit, Vector). Slides were rinsed in dis-
tilled water, dehydrated through graded concentrations of
ethanol, cleared in xylene and coverslipped using Cyto-
seal 60 mounting medium (Richard-Allan Scientific,
Kalamazoo, MI). Negative controls consisted of substitut-
ing normal mouse IgG (Vector) for the primary antibody,
using the same protein concentration as for the primary
antibody. No immunoreactivity was present on these neg-
ative control slides. Staining of the contralateral striatum
served as an additional negative control.
MHC I and II, CR-3, CD4, and CD8 immunohistochemistry
BrdU staining (see above) was used to determine optimal
sections for evaluating the host cellular immune response
to MSC. Each antibody for detection of immune cell sur-
face antigens was applied to three sections per animal. The
three sections were not equally spaced, but were chosen to
include the regions where BrdU immunoreactivity was
moderate to strong. The interval between sections aver-
aged approximately 320 μm, with a range of 140 to 520
μm. The following monoclonal antibodies were used (all
from Serotec, Raleigh, NC): OX18 (1:500), which recog-Journal of Neuroinflammation 2009, 6:17 http://www.jneuroinflammation.com/content/6/1/17
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nizes rat MHC class I antigen, OX6 (1:500), which recog-
nizes rat MHC class II antigen appearing on B
lymphocytes, certain epithelial cells, dendritic cells, some
macrophages, and activated microglia (commonly used
for microglial detection), OX42 (1:200), which recognizes
the CR3 receptor expressed on most macrophages, resting
and activated microglia, and monocytes (commonly used
for microglial detection), W3/25 (1:500), which recog-
nizes the CD4 antigen appearing on T-helper lym-
phocytes, microglia and some macrophages, and OX8
(1:400), which recognizes the CD8 antigen appearing pri-
marily on cytotoxic T-lymphocytes. These antibodies have
been used in previous investigations of the immune
response following transplantation of other types of cells
into the brain [59-61]. Procedures were as described for
BrdU immunocytochemistry, except that sections were
not pre-treated with citrate buffer, TBS molarity was 0.05
M, and antibody dilution buffer did not include BSA.
Tyrosine hydroxylase (TH) immunohistochemistry
Striatal and substantia nigra sections were stained for TH
using similar procedures to those described for MHC anti-
gens, except that 0.3% hydrogen peroxide/2% NHS in TBS
was used to quench endogenous peroxidase activity. The
anti-TH monoclonal antibody (LNC-1, provided by Dr. G.
Kapatos, Wayne State University, Detroit, MI) was diluted
to 1:3,000.
Quantitation of immunocytochemical staining
Immunocytochemical staining was assessed using a
Nikon Eclipse E400 microscope with a 10× or 40× objec-
tive and an Optronics DEI-750 video camera connected to
a computerized image analysis system (BIOQUANT-R&M
Biometrics, Inc, Nashville, Tennessee, USA). Immunore-
active staining for MHC I and II, CR-3, and CD4 was
quantified in terms of both its intensity (i.e. relative opti-
cal density) and the percent area occupied in the region of
interest. To quantify immunostaining intensity, optical
density was measured in four equivalent fields (75 μm2
per field) adjacent to the injection tract where immunore-
activity was most intense, and the measurements obtained
for the four fields were averaged for each section. Densit-
ometric measurements were corrected for background
intensity. Optical density did not differ between treatment
groups for any of the cell surface antigens, therefore these
data are not presented. To measure the percent area occu-
pied by immunoreactivity, a threshold for positive stain-
ing was determined for each cell surface antigen, then this
setting was used on all sections to measure the area of the
thresholded pixels in the delineated region of interest. The
"invert threshold" function was used to determine the
area of the non-thresholded pixels in the same region.
This was necessary in order to determine the percentage of
the region of interest occupied by immunoreactive pixels.
The highest measurement for percent immunoreactivity
among the three slides was used for statistical analysis.
The striatum was delineated by the following boundaries:
medial: lateral ventricle; dorsal and lateral: corpus callo-
sum, and ventral: anterior commissure. Because individ-
ual cells stained for BrdU or CD8 could be visualized, the
total number of these cells was counted on 40× images. As
a relative estimate of the number of remaining MSC in the
striatum, the number of BrdU-positive cells was counted
in every ninth section throughout the striatum and then
the counts from these sections were totaled for each stria-
tum. To quantitate TH immunoreactivity in the striatum,
the intact (contralateral) striatum was used to determine
the threshold for what was considered to be positive TH
staining, and then the area of the pixels that exceeded this
threshold was measured for both striata. The same
method was used to determine TH immunoreactivity in
the substantia nigra: the threshold for positive immunore-
activity was determined for the substantia nigra on the
non-lesioned side, then the area of the thresholded pixels
was measured for both sides of the nigra. TH immunore-
activity in the substantia nigra was evaluated in the pars
compacta and pars reticulata, but not the ventral tegmen-
tal area. All measurements were made in a blinded fash-
ion.
Statistics
Nonparametric statistics including the Kruskall-Wallis test
and the Wilcoxon Two-Sample test were performed on the
immunocytochemical staining data and on the behavioral
data using SAS statistical software (SAS, Cary, North Caro-
lina, USA) to evaluate treatment effects. The level of signif-
icance was set at p < 0.05 for all analyses. Spearman's rank
correlation coefficients were calculated to assess the
strength of association between the different host
immune markers, as well as the strength of association




There was considerable variability in behavioral scores
within treatment groups, most likely because of the vary-
ing loss of nigrostriatal dopamine neurons within each
group. Evaluation for statistical differences between treat-
ment groups using the Kruskal-Wallis test was not useful
because of the large variation in behavioral deficits and
small sample sizes. (The sample sizes were chosen on the
basis of a power analysis from data from a pilot investiga-
tion performed in our laboratory; however, the lesion size
varied more in the present study than it did in the pilot
study.) Data are therefore presented in Fig. 1 as scatter
plots of the individual behavioral scores as a function of
the degree of lesioning (i.e. percent loss of TH immunore-
activity in the substantia nigra). An analysis of covariance
model was fit to evaluate the relationship between lesionJournal of Neuroinflammation 2009, 6:17 http://www.jneuroinflammation.com/content/6/1/17
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Scatter plots of individual behavioral scores Figure 1
Scatter plots of individual behavioral scores. Relationship between lesion severity (percent loss of tyrosine hydroxylase 
[TH] immunoreactivity in the substantia nigra [SN]) and behavioral scores in PBS-treated (open circles, n = 6) and MSC-trans-
planted (closed circles, n = 11) animals. The behavioral performance of nonlesioned naive rats is indicated by the shaded region 
(mean ± SEM). A linear regression analysis was performed on the scatter plots (solid line); correlation coefficients are listed for 
each analysis. Amphetamine- and apomorphine-induced rotation was not linearly related to lesion severity, therefore no linear 
regression is shown for these plots. Two of the MSC-transplanted animals (indicated by asterisks) with nearly complete nigral 
lesions performed more similarly to animals with partial lesions in some of the behavioral tests.Journal of Neuroinflammation 2009, 6:17 http://www.jneuroinflammation.com/content/6/1/17
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severity and performance on each behavioral test. The
slope of the line relating the behavioral scores to lesion
severity did not statistically differ between MSC- and PBS-
treated animals; however, lesion severity was a significant
predictor of forelimb stepping and cylinder test scores.
Vigorous amphetamine- and apomorphine-induced turn-
ing was seen only in those animals with nearly complete
dopaminergic lesions (> 95% loss of substantia nigra TH
immunoreactivity). However, two of the three rats that
had nearly complete dopaminergic lesions and that
received Wistar-derived MSC did not rotate following
apomorphine challenge. These animals also had smaller
deficits on the stepping and cylinders tests than the other
animals with similar-sized lesions. Interestingly, these
two animals had the highest numbers of striatal BrdU-
labeled MSC among all of the transplanted animals
(15,119 and 13,005 BrdU+ cells vs. 3,895 ± 1,099 [mean
± S.E.M.] for all other animals receiving MSC). The other
rat in this group that rotated following apomorphine
treatment had only 475 BrdU+ cells. Except for this obser-
vation, MSC transplantation did not appear to reduce the
deficits on any of the other behavioral tests.
BrdU staining
BrdU-labeled MSC were easily discriminated from BrdU-
labeled microglia and/or macrophages that had phagocy-
tosed BrdU from degenerating MSC, as reported previ-
ously [43]; intense BrdU immunoreactivity was present in
the nucleus of MSC, whereas lighter, cytoplasmic staining
was observed in host cells [29]. Only cells with strong
nuclear BrdU labeling were counted as MSC, as verified on
images captured with the 40× objective. MSC were clearly
detectable at 3 weeks post-transplantation (Fig. 2). The
majority of MSC were clustered along the injection tract
within the denervated striatum, although in a few cases
moderate numbers of these cells were also found in the
overlying cortex (around the injection tract) and in the
corpus callosum. No BrdU immunoreactivity was
detected in either the contralateral (nontransplanted)
striatum or in histological sections from PBS-treated con-
trols (Fig. 2A). In some animals, MSC were detected as far
as 750 μm from the center of the injection tract (Fig. 2B).
MSC counts (mean number of BrdU+ cells ± S.E.M.) for
each group are shown in Fig 2D. BrdU-positive cells were
detected in the striatum in all animals receiving MSC, and
the numbers of these cells detected in the 6-OHDA-
lesioned Wistar rats receiving Wistar MSC tended to be
greater than in those receiving ACI MSC (p = 0.055). Wis-
tar MSC tended to migrate farther from the implantation
site than did ACI MSC (Fig. 2B vs. 2C). The anterior-to-
posterior extent of BrdU immunoreactivity, as estimated
from staining every ninth section throughout the entire
striatum, was 883 ± 101 μm (mean ± SEM) for Wistar
MSC and 620 ± 83 μm for ACI MSC. The region of BrdU
staining, as determined in the anterior-to-posterior direc-
tion, ranged from 220 μm to 1540 μm. BrdU staining was
also performed on substantia nigra sections to determine
whether intrastriatally delivered MSC migrated to the site
of the 6-OHDA lesion. No BrdU+ cells were detected in
substantia nigra sections from MSC-treated animals.
TH immunoreactivity
TH immunoreactivity was generally absent in the areas
occupied by BrdU+ cells, suggesting that the implanted
MSC did not acquire the ability to synthesize TH, the rate-
limiting enzyme for dopamine production (Fig. 3A). TH
immunoreactivity in the lesioned striatum was variably
reduced (by 4 to 99%) in comparison with the intact
(contralateral) striatum (Fig 3B). TH immunoreactivity in
the substantia nigra was highly correlated with TH immu-
noreactivity in the striatum (Spearman rho = 0.91, p <
0.0001; Fig. 3). There were no significant differences in
the intensity of TH staining among the treatment groups.
Cellular immune response in host striatum
Complement receptor 3 (CR3) immunoreactivity
Widespread immunoreactivity to OX42 was observed in
all three groups (Fig. 4A–C). This was expected, because
OX42 is expressed on resting microglia as well as reactive
microglial cells and macrophages. Immunoreactivity in a
remote area of the denervated striatum was used to deter-
mine the relative staining density of resting microglia, and
this value was then subtracted from measurements made
near the implantation site. Immunostaining was intense
along the needle track, and large numbers of hypertrophic
cells (most likely activated macrophages) were observed
surrounding and within the implantation site. CR3
immunoreactivity (% immunoreactivity) in the MSC-
injected groups was twice that of PBS-injected controls (p
< 0.05) (Fig. 4D). There was no difference in CR3 immu-
noreactivity between the Wistar MSC- and ACI MSC-trans-
planted groups.
MHC immunoreactivity
In MSC-transplanted animals, a large area of the host
striatum was infiltrated with MHC class I and class II
immunoreactive cells, although MHC expression was
most intense surrounding and within the injection tract
(Figs. 5 and 6). In contrast, in the PBS control group,
staining for these antigens was less intense and closely
confined to the injection tract. Many MHC-immunoreac-
tive cells around the injection tract exhibited microglia-
like morphology. MHC class I immunoreactivity occupied
15–20% of the striatum in MSC-transplanted animals,
compared to less than 5% in PBS controls (p < 0.05; Fig.
5D). MHC class II immunoreactivity was present in 20–
40% of the striatum in MSC-transplanted animals (also p
< 0.05 vs. PBS-injected controls; Fig. 6D). MHC immuno-
reactivity was not significantly different between the two
MSC-transplanted groups.Journal of Neuroinflammation 2009, 6:17 http://www.jneuroinflammation.com/content/6/1/17
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Lymphocyte immunoreactivity
The W3/25 antibody, which detects CD4+  (T helper-
inducer) lymphocytes, stained round cells with typical
lymphocytic morphology as well as stellate cells resem-
bling microglia, although the staining of these latter cells
was weaker (Fig. 7A–C). A small population of W3/25+
cells was present in and around the needle tract in both
MSC-treated groups. In control animals, the majority of
W3/25-immunoreactive cells surrounding the needle
track resembled microglia, although a few cells with lym-
phocytic morphology were also present. W3/25 immuno-
reactivity was four-fold higher in MSC-transplanted
animals than in PBS-infused controls (p < 0.05; Fig. 7D).
There was no significant difference in W3/25 immunore-
activity between the two MSC-transplanted groups.
In contrast to W3/25, the OX8 antibody, which detects
CD8+ (T cytotoxic-suppressor) lymphocytes, stained only
cells with typical lymphocytic morphology (Fig. 8A–C).
There were far fewer OX8+ than W3/25+ lymphocytes in
and around the injection tract. Few or no OX8+ cells were
detected in PBS control animals. OX8 staining was signif-
icantly increased in the MSC-transplanted groups com-
pared with PBS-injected controls (Fig. 8D) (p < 0.05), and
BrdU immunoreactivity in striatum Figure 2
BrdU immunoreactivity in striatum. (A) Lack of immunoreactivity in the PBS-infused striatum. (B-C) BrdU+ cells in Wis-
tar rats receiving either Wistar (WIS) MSC or ACI MSC, respectively. (D) The numbers of BrdU+ cells detected in every ninth 
20 μm section throughout the striatum were totaled for each rat receiving either WIS MSC (n = 6) or ACI MSC (n = 4). Graph 
shows mean values ± SEM. Closed circles indicate values from individual animals. Scale bars = 80 μm.Journal of Neuroinflammation 2009, 6:17 http://www.jneuroinflammation.com/content/6/1/17
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similar numbers of OX8+ cells were present in the two
groups of MSC-transplanted animals.
Correlational analyses
When data from the two groups of allogeneic recipients
were combined, a moderate positive association was
present between MHC class I and II staining in the stria-
tum (r = 0.56). In addition, W3/25 (CD4) and OX8
(CD8) immunoreactivities were both moderately corre-
lated with OX42 staining (r values = 0.60 and 0.52, respec-
tively). No other correlations were present between the
host cellular immune markers. A strong positive associa-
tion was present between the numbers of striatal BrdU+
cells and the extent of striatal MHC class II immunoreac-
tivity (r = 0.77), but not for any other immune marker. No
correlations were detected between the numbers of BrdU+
cells and TH immunoreactivity in either the striatum or
the substantia nigra.
Discussion
In contrast to the in vitro studies cited earlier, our results
indicate that a marked cellular immune response occurs
when MSC are implanted into brains of allogeneic recipi-
ents. MHC class I- and class II-expressing cells and CD4+
and CD8+ lymphocytes were increased in the host stria-
tum in both the ACI-to-Wistar and Wistar-to-Wistar sys-
tems. This study did not include Wistar-to-ACI MSC
transplantation because the MHC differences would have
been the same as for the ACI-to-Wistar transplant. Because
rat strains differ in their ability to generate immune
TH immunoreactivity in striatum and substantia nigra Figure 3
TH immunoreactivity in striatum and substantia nigra. Low power photomicrographs of TH immunostaining in the 
striatum (A-B) and the substantia nigra (C-D) from a rat receiving Wistar MSC. Similar staining was seen in animals receiving 
ACI MSC and in PBS-treated controls. Note the loss of TH immunoreactivity in the lesioned side (A, C) compared to the unle-
sioned side (B, D). Arrow indicates the needle track from the injection. Scale bars = 200 μm.Journal of Neuroinflammation 2009, 6:17 http://www.jneuroinflammation.com/content/6/1/17
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responses [62], we cannot rule out the possibility that
strain-dependent differences in immune function may
have affected the ACI and Wistar responses to allogeneic
MSC. Outbred rats have frequently been used as recipients
for CNS grafts (see, for example, references 41 and 49).
Because ACI is an inbred strain, ACI-to-ACI transplanta-
tion would be a syngeneic system; this would provide no
information about the local immune response to MSC
transplanted into unrelated individuals (i.e. a "universal
donor" paradigm), which was what we wished to model.
Previous studies have reported that MSC transplanted into
syngeneic recipients survive well and elicit only a short-
lived host immune response after their transplantation
into the CNS [47,63]. Although Wistar-to-Wistar trans-
plants have been referred to as syngeneic [41], this is
incorrect; because Wistar is an outbred strain, these trans-
plants are actually allografts.
As stated earlier, cultured MSC typically express low to
moderate levels of MHC class I antigens but generally do
not express MHC class II or co-stimulatory molecules, and
they secrete immunosuppressive cytokines [30]. An expla-
nation for our contrasting finding of a strong cellular
immune response in the brain following MSC administra-
CR3 (OX42) immunoreactivity in striatum Figure 4
CR3 (OX42) immunoreactivity in striatum. (A-C) Widespread immunoreactivity to complement receptor 3 (CR3) in 
PBS-infused striatum, Wistar (WIS) MSC-implanted striatum, and ACI MSC-implanted striatum, respectively, in the same rats 
shown in Fig. 2. (D) The percent area (means ± SEM) of striatum (lesioned side) occupied by CR3 immunoreactivity in the 
MSC-injected groups (n = 4 – 6) was twice that of PBS-injected controls (n = 5; *p < 0.05). Scale bars = 80 μm.Journal of Neuroinflammation 2009, 6:17 http://www.jneuroinflammation.com/content/6/1/17
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tion is that MSC expression of MHC antigens and cytokine
production may be altered in vivo. For example, it was
recently reported that MSC lose their ability to downregu-
late T-cell immune responsiveness after allotransplanta-
tion [64]. The immunosuppressive properties of MSC
may, in fact, be dose-dependent [33,34,65]. Another pos-
sible explanation for the discrepancy between the in vitro
literature and our results could be tissue damage resulting
from the transplantation procedure, which leads to an
influx of inflammatory cells [59,61]. Brain injury disrupts
the blood-brain barrier, permitting entrance of immune
cells from peripheral blood [49,60]. The presence of these
cells in the transplantation site could prime the brain for
an immunological response to allogeneic MSC. In sup-
port of this possibility, transplantation procedures that
minimize brain trauma and/or inflammation have been
found to decrease graft rejection [66,67]. MSC adminis-
tered intravenously have been suggested to avoid the host
immune response [41], although the latter study exam-
ined only the systemic immune response (i.e. peripheral
blood T cell priming, and antibody production) to these
cells. Finally, mechanical injury to MSC at the time of
MHC I (OX18) immunoreactivity in striatum Figure 5
MHC I (OX18) immunoreactivity in striatum. (A) MHC class I staining in PBS controls was closely confined to the injec-
tion tract. (B-C) In animals receiving Wistar (WIS) MSC or ACI MSC (same rats shown in Fig. 2), a large area of the host stria-
tum was infiltrated with MHC class I immunoreactive cells, although MHC expression was most intense surrounding and within 
the injection tract. (D) MHC class I staining occupied 15–20% of the striatum in MSC-transplanted animals, compared to less 
than 5% in PBS controls (graph shows means ± SEM; *p < 0.05). Scale bars = 80 μm.Journal of Neuroinflammation 2009, 6:17 http://www.jneuroinflammation.com/content/6/1/17
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implantation could also cause these cells to be seen as
"foreign" by the host immune system. Although, as stated
above, MSC viability was 83–95% prior to their transplan-
tation, their viability was not assessed a second time after
they were infused; therefore the possibility that some cells
may have been damaged during this process cannot be
ruled out.
MSC were still detected in the striatum at 3 weeks post-
transplantation despite the presence of an active immune
response to them. Previous studies have found that MSC
allografts and xenografts can persist long-term in immu-
nocompetent hosts [68,69], although immunosuppres-
sion may improve cell survival in these models [45,47].
Our results suggest that an active host immune response
may not be successful in clearing these cells from the
brain, as occurs following transplantation of other cell
types [59,61,70]. Evaluation of additional time points
would be necessary in order to clarify the relationship
between the immune response in the CNS and long-term
survival and function of allogeneic MSC.
MHC II (OX6) immunoreactivity in striatum Figure 6
MHC II (OX6) immunoreactivity in striatum. (A) MHC class II staining in PBS controls was closely confined to the injec-
tion tract. (B-C) In animals receiving Wistar (WIS) MSC or ACI MSC (same rats shown in Fig. 2) MHC class II immunoreactiv-
ity was widespread in the striatum, but it was most intense surrounding and within the injection tract. (D) MHC class II 
staining was present in 20–40% of the striatum in MSC-transplanted animals, compared to less than 10% in PBS controls (graph 
shows means ± SEM; *p < 0.05). Scale bars = 80 μm.Journal of Neuroinflammation 2009, 6:17 http://www.jneuroinflammation.com/content/6/1/17
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No significant differences with regard to MSC survivabil-
ity or host immune response were observed between the
two types of allografts, although higher numbers of BrdU+
cells tended to be present in the Wistar-to-Wistar trans-
plants (p = 0.055). When data from the two groups of
recipients were combined, the number of BrdU+ cells was
positively correlated with MHC class II immunoreactivity,
suggesting that allogeneic MSC may upregulate MHC class
II expression (presumably, on microglia) in the brain. The
density of OX42+ cells in MSC-treated animals was twice
that of PBS-treated controls, indicating that the presence
of MSC resulted in a local increase in microglia; this could
have been due to secretion of chemotactic and/or prolifer-
ation-promoting factors by the MSC [71,72]. Our princi-
pal conclusion from this study is that, although allogeneic
MSC stimulate a marked host cellular immune response
in the brain, this response is not sufficient to clear the
MSC, at least not by three weeks post-implantation. Stud-
ies investigating the host immune response at additional
time points are required to determine the duration of this
response and whether it eventually clears allogeneic MSC
from the striatum. MSC survival might not, in fact, be cor-
CD4 (W3/25) immunoreactivity in striatum Figure 7
CD4 (W3/25) immunoreactivity in striatum. (A) The majority of CD4+ cells in PBS-infused animals resembled microglia, 
although a few cells with lymphocytic morphology were also present. (B-C) CD4+ cells with lymphocytic morphology were 
present in and around the needle tract in Wistar (WIS) MSC-treated and ACI MSC-treated animals (same rats shown in Fig. 2). 
(D) CD4 (W3/25) immunoreactivity was four-fold higher in MSC-transplanted animals than in PBS-infused controls (graph 
shows means ± SEM; *p < 0.05). Scale bars: = 80 μm.Journal of Neuroinflammation 2009, 6:17 http://www.jneuroinflammation.com/content/6/1/17
Page 14 of 18
(page number not for citation purposes)
related with the extent of the host immune response to
them; if so, then this could explain why the two types of
allografts showed similar levels of immune responses.
Finally, the possibility cannot be ruled out that the trend
for increased MSC survival in the Wistar-to-Wistar system
could be due, in part, to differences in the numbers of via-
ble MSC implanted. Although prepared in identical fash-
ion, the suspensions of ACI MSC were more viscous than
Wistar MSC suspensions, so more of these cells may have
been injured during their infusion into the brain.
Microenvironmental conditions in the brain following
acute injury, including the presence of oxygen radicals,
excitotoxins, low concentrations of energy substrates,
and/or alteration of local pH, may influence the survival
and function of transplanted MSC. Further, the influx of
inflammatory cells induced by tissue injury secondary to
the surgical procedure may exacerbate the immune
response to allogeneic cells. Introducing MSC into the
brain by less invasive approaches, such as intravenous or
intracarotid injections [13,41,69], or using techniques to
minimize the degree of tissue injury might therefore
improve their survival and function.
We cannot rule out that some of the BrdU+ cells could be
microglia which had phagocytosed MSC, as suggested by
CD8 (OX8) immunoreactivity in striatum Figure 8
CD8 (OX8) immunoreactivity in striatum. (A) Little or no CD8 staining was observed in PBS control animals. (B-C) 
Few CD8+ cells were detected in and around the injection tracts of Wistar MSC-treated and ACI MSC-treated animals (same 
rats shown in Fig. 2). (D) The numbers of CD8+ (OX8) cells were significantly increased in the MSC-transplanted groups com-
pared with PBS-injected controls (graph shows means ± SEM;*p < 0.05). Scale bars = 80 μm.Journal of Neuroinflammation 2009, 6:17 http://www.jneuroinflammation.com/content/6/1/17
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earlier studies [43,73], and this could have increased our
MSC counts. However, several factors suggest that this is
not case. We followed the procedure described by Li et al
[29] to distinguish BrdU-labeled MSC from BrdU+ phago-
cytic cells by their relative staining patterns: BrdU+ MSC
should display nuclear staining, whereas BrdU+ phago-
cytes should have cytoplasmic staining. Both of these
staining patterns were observed, therefore only cells with
strong nuclear staining were counted as MSC. In addition,
the distribution and pattern of staining for BrdU-labeled
cells and microglia was not the same (e.g., compare the
staining in Fig. 2B with Figs. 4B and 5B, which represent
serial sections from the same rat). Double-labeling was
not performed, therefore we do not know whether the
BrdU+ cells expressed the CR3 receptor, MHC I antigens,
or MHC II antigens in vivo. However, our finding that the
allogeneic MSC induced a strong host immune response
in the striatum suggests that these cells did express MHC
antigens, therefore our staining for MHC antigens could
indicate MSC as well as microglia; further, some reports
suggest that MSC may be capable of differentiating into
glial cells, including microglia [15,27]. Because of these
possibilities, even if cells staining for both BrdU and
microglial antigens would be detected, this would not
necessarily imply that BrdU transfer from MSC to micro-
glia had occurred. The observation that two of the animals
which received MSC had very low numbers of BrdU+ cells
in the striatum implies that transfer of BrdU to host cells
was likely to have been negligible. In our preliminary
studies we identified male donor MSC in female recipi-
ents by their Y-chromosome using in situ hybridization
(data not shown). With this technique, MSC were
detected in the implanted striatum of allogeneic 6-
OHDA-hemilesioned rats after 13 weeks, supporting our
findings in the present study that at least some MSC can
remain in the brain despite a marked immune response to
them. We chose to use BrdU immunostaining, rather than
in situ hybridization, for detecting MSC in this study
because of the more quantitative nature of BrdU staining.
Although the main goal of this study was to evaluate the
immune response to intrastriatally-administered MSC, a
secondary goal was to investigate the ability of these cells
to prevent loss of nigrostriatal dopamine and associated
behavioral deficits in an animal model of PD. The
dopamine loss in our animals varied from 40% to 100%.
Because of this variability, our study lacked sufficient sta-
tistical power to determine the therapeutic effects of MSC
in these animals. Interestingly, the two animals with the
highest numbers of striatal BrdU+ MSC failed to rotate fol-
lowing apomorphine, although both animals had nearly
complete 6-OHDA lesions. Apomorphine-induced rota-
tion is used to identify animals with complete (or nearly
complete) unilateral dopaminergic lesions; typically, only
animals with greater than 90% loss of the nigrostriatal sys-
tem rotate after administration of a low dose of apomor-
phine [74]. Although the data from these two animals
suggest that MSC may be able to reduce behavioral deficits
in animals with extensive dopamine depletion, studies
with larger sample sizes will be required to determine if
these observations can be confirmed. The low numbers of
MSC in many of the animals may have contributed to the
negative behavioral outcome in our study. Other studies
evaluating the value of MSC in restoring function in the 6-
OHDA rat model have reported varying results [16,18-
22,75] with some of these studies reporting improvement
only with genetically modified or neural-induced MSC
[16,18,22]. A possible explanation for these differing
results may be the numbers of MSC surviving in the brain
after transplantation.
In contrast to previous studies, MSC were administered
immediately following 6-OHDA lesioning. When 6-
OHDA is administered into the medial forebrain bundle
or substantia nigra, degeneration of dopaminergic neu-
rons occurs within 24–72 hr [76]. Because the beneficial
effects of MSC in the brain have been suggested to be due
to their secretion of neurotrophic factors [23-25], we
hypothesized that MSC administered at the time of lesion-
ing might protect nigral neurons and their striatal termi-
nals from the damaging effects of 6-OHDA. Such a
strategy has the potential for therapeutic use in early PD
to support and protect dopaminergic neurons against
whatever factors are responsible for the ongoing neuronal
loss. Transplants that are performed weeks after 6-OHDA
lesioning, when dopaminergic cell loss has already been
established, would more accurately model MSC adminis-
tration to subjects with advanced PD; however, when
early detection of the disease becomes possible, then
effective neuroprotective treatments which can be admin-
istered prior to the extensive loss of dopamine neurons
will be an important strategy. The same day lesion/trans-
plant paradigm also allowed us to investigate whether
intrastriatally transplanted MSC would migrate to the site
of ongoing dopaminergic cell loss, i.e. the substantia
nigra. Previous studies have indicated that MSC migrate to
sites of tissue injury [13,14,77], perhaps due to locally-
produced chemokines [78]. We hypothesized that in the
acute 6-OHDA lesion model, chemoattraction of MSC
would be greatest when dopamine neurons were dying.
However, we found the loss of TH immunoreactivity in
both striatum and substantia nigra to be similar between
MSC-transplanted and PBS-control animals, and no
BrdU+ cells were detected in the substantia nigra. In con-
trast to our results with MSC, other types of cellular grafts
have been shown to preserve nigrostriatal dopamine neu-
rons and to reduce motor deficits when introduced at the
time of 6-OHDA lesioning [7]. Additional studies are
therefore warranted to determine the effects of MSCJournal of Neuroinflammation 2009, 6:17 http://www.jneuroinflammation.com/content/6/1/17
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administered at different times in relation to 6-OHDA
lesioning.
Conclusion
MSC, when implanted into the brains of allogeneic rats,
are detectable at post-implantation days 22–24 despite
the presence of an active cellular immune response to
them. Our findings are consistent with other studies indi-
cating that allogeneic and xenogeneic MSC can provoke
an immune response in vivo [39,43,44,46,47]. Whether
this response contributed to the failure of MSC to reduce
the behavioral deficits in the rats in this study that were
extensively lesioned is not known. Further studies are
indicated in which allogeneic MSC survival and therapeu-
tic efficacy in animal models of PD will be compared
between various routes of administration, at different
time points, and in both immunocompetent and immu-
nosuppressed animals.
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